Evotec (EVTCY) Stock Price, News & Analysis

Company Overview

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Key Stats

• Today's Range: $3.50 to $3.58
• 50-Day Range: $3.54 to $4.34
• 52-Week Range: $14.22 to $26.57
• Volume: 71,065 shs
• Average Volume: 2,407 shs
• Market Capitalization: $1.17 billion
• P/E Ratio: 8.63
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EVTCY Stock Analysis - Frequently Asked Questions

How have EVTCY shares performed this year?

Evotec's stock was trading at $4.16 on January 1st, 2025. Since then, EVTCY stock has decreased by 14.9% and is now trading at $3.54.

When did Evotec's stock split?

Shares of Evotec split before market open on Wednesday, October 20th 2021.The 3-1 split was announced on Wednesday, October 20th 2021. The newly created shares were distributed to shareholders after the market closes on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Does Evotec have any subsidiaries?

Evotec subsidiaries include these companies: Central Glass Germany. GmbH, Central Glass Germany, Rigenerand Srl, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, Aptuit, Cyprotex, and others.

How do I buy shares of Evotec?

Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:EVTCY
• CIK: 1412558
• Web: www.evotec.com
• Phone: (494) 056-0810
• Fax: 49-40-5608-1222
• Employees: 4,200
• Year Founded: 1993

Profitability

• EPS (Trailing Twelve Months): $0.41
• Trailing P/E Ratio: 8.63
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $7.14 million
• Net Margins: 20.85%
• Pretax Margin: 23.90%
• Return on Equity: 16.02%
• Return on Assets: 7.81%

Debt

• Debt-to-Equity Ratio: 0.53
• Current Ratio: 2.57
• Quick Ratio: 2.50

Sales & Book Value

• Annual Sales: $572.16 million
• Price / Sales: 2.04
• Cash Flow: $0.03 per share
• Price / Cash Flow: 105.53
• Book Value: $2.52 per share
• Price / Book: 1.40

Miscellaneous

• Outstanding Shares: 330,221,000
• Free Float: N/A
• Market Cap: $1.17 billion
• Optionable: Not Optionable
• Beta: 0.98